Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PLX-R18 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PLX-R18 | EXPERIMENTAL | Dose Escalation- first three subjects will be enrolled in the low dose cohort, 6 subjects in the intermediate-dose cohort, and 15 subjects in the high dose cohort. |
| Name | Type | Description |
|---|---|---|
| PLX-R18 | BIOLOGICAL | Intramuscular (IM) administration of PLX-R18 |
Inclusion Criteria: 1. Age ≥18 years. 2. At least 3 months after HCT, either autologous or allogeneic (of any source, with any preparatory regimen, for any indication), prior to study treatment. 3. Sustained platelet count ≤50,000/µL, and/or sustained Hb ≤8 g/dL and/or sustained ANC ≤1000/mm3, attr...
PLX-R18 is an investigational monoclonal antibody developed by Pluri Inc. It is being studied for incomplete hematopoietic recovery following hematopoietic cell transplantation, a condition in which blood cell production does not fully recover after a transplant. It has completed a Phase 1 clinical trial and is not approved for commercial use.
PLX-R18 is being developed for incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT). The condition involves inadequate restoration of blood cell production after transplant. The only clinical study of PLX-R18 to date enrolled 21 adult subjects with this condition in the United States and Israel.
PLX-R18 is developed by Pluri Inc., which trades under the ticker PLUR. Pluri is the sponsor of the clinical program evaluating the drug in incomplete hematopoietic recovery after hematopoietic cell transplantation.
PLX-R18 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA or any other regulatory agency. One Phase 1 trial has been completed, and no active trials of PLX-R18 are currently listed.
PLX-R18 has been studied in one completed Phase 1 trial, NCT03002519, titled Safety Evaluation of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation. The trial enrolled 21 adults across sites in the United States and Israel and was an uncontrolled, non-randomized study.